Presentation is loading. Please wait.

Presentation is loading. Please wait.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Published byAndré Castilho César Modified over 6 years ago

Similar presentations

Presentation on theme: "Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association."— Presentation transcript:

1 Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets.
Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Kaplan–Meier survival analysis of TCGA skin cutaneous melanoma (A), breast invasive carcinoma (B), and prostate adenocarcinoma (C) provisional datasets, comparing control patients (blue) and patients harboring specified alterations in JAK1 and JAK2 (red). Frequency and distribution of combined JAK1 and JAK2 alterations are shown within each set of Kaplan–Meier plots. Significance testing of overall survival was performed using log-rank analysis. Daniel Sanghoon Shin et al. Cancer Discov 2017;7: ©2017 by American Association for Cancer Research

Download ppt "Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association."

Similar presentations

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.
P

P
Lung squamous cell carcinoma

Lung squamous cell carcinoma
Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.
(A) Schematic diagrams demonstrating the HER2 mutational heterogeneity among and between cases of invasive breast cancer (n=963), bladder urothelial cancer.

(A) Schematic diagrams demonstrating the HER2 mutational heterogeneity among and between cases of invasive breast cancer (n=963), bladder urothelial cancer.
Dose-escalation patient response.

Dose-escalation patient response.
Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
سرطان الثدي Breast Cancer

سرطان الثدي Breast Cancer
ML criticality in clinical outcome across cancer types.

ML criticality in clinical outcome across cancer types.
Prognostic significance of DDB2 in ovarian cancer.

Prognostic significance of DDB2 in ovarian cancer.
Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA.

Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA.
Altered interferon signaling with JAK1 loss-of-function mutation in M431 and interferon gamma-inducible PD-L1 expression by 48 melanoma cell lines. Altered.

Altered interferon signaling with JAK1 loss-of-function mutation in M431 and interferon gamma-inducible PD-L1 expression by 48 melanoma cell lines. Altered.
Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.
Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.
Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p
AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,

AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,
Q-Q plot of observed P values against theoretical P values for factor analysis (red dots) and single gene–based methods (in blue). Q-Q plot of observed.

Q-Q plot of observed P values against theoretical P values for factor analysis (red dots) and single gene–based methods (in blue). Q-Q plot of observed.
Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.

Similar presentations

Ads by Google